Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2026-02-23 @ 8:57 PM
Study NCT ID:
NCT05320692
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-11
First Post:
2022-04-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SHR-1210-Ⅲ-336
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None